Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal — Organon & Co.

Event summary

Sun Pharma to acquire Organon for $14.00 per share in an all-cash transaction valued at $11.75 billion.
The deal is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.
Organon reported $6.2 billion in revenue and $1.9 billion in Adjusted EBITDA for the year ended December 31, 2025.
Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks.

The big picture

This acquisition positions Sun Pharma as a top 25 global pharmaceutical company, significantly expanding its presence in women’s health and biosimilars. The deal reflects a broader trend of consolidation in the pharmaceutical industry, driven by the need for scale and diversification in an increasingly competitive market. With combined revenues of $12.4 billion, the merged entity aims to enhance long-term value creation through synergies and strategic growth opportunities.

What we're watching

Integration Challenges: How Sun Pharma will manage the integration of Organon’s global operations and product portfolio, particularly in women’s health and biosimilars.
Regulatory Approvals: The pace at which regulatory approvals are obtained and any potential conditions or restrictions imposed on the merger.
Financial Leverage: Whether Sun Pharma can sustain its post-transaction Net Debt/EBITDA ratio of 2.3x and effectively deleverage over time.